Biodesix Inc. (BDSX) Tops Q4 EPS by 1c, provides guidance

Biodesix Inc. (NASDAQ: BDSX) reported Q4 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $15.62 million.

GUIDANCE:

Biodesix Inc. sees FY2024 revenue of $65-68 million, versus the consensus of $64.526 million.

For earnings history and earnings-related data on Biodesix Inc. (BDSX) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• flyExclusive (FLYX) Misses Q2 EPS by 3c
• Century Therapeutics, Inc. (IPSC) Misses Q2 EPS by 6c